NCT00635323View on ClinicalTrials.gov

Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

May 31, 2005

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Irinotecan plus capecitabine

Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for

Trial Locations (9)

112

Pfizer Investigational Site, Taipei

204

Pfizer Investigational Site, Keelung

200433

Pfizer Investigational Site, Shanghai

Unknown

Pfizer Investigational Site, Hong Kong SAR

Pfizer Investigational Site, Taipei

135-710

Pfizer Investigational Site, Seoul

136-705

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

152-703

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00635323 - Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter